Recent Company News

• 07:19 AM ET Jul 30, 2025
  

  Can-Fite BioPharma achieves over 50% enrollment milestone in Phase 2a trial of Namodenoson for pancreatic cancer ($0.71, 0.00)

• 12:42 PM ET Jul 28, 2025
  

  Can-Fite BioPharma shares to resume trading at 1240ET ($0.84, -0.14)

• 12:27 PM ET Jul 28, 2025
  

  Can-Fite BioPharma announces pricing of public ADS and warrants offering ($0.84, -0.14)

• 12:12 PM ET Jul 28, 2025
  

  Can-Fite BioPharma halted; news pending ($0.84, -0.14)

• 07:16 AM ET Jul 28, 2025
  

  Can-Fite announces study from UCLA demonstrates Piclidenoson as a treatment for vascular dementia ($0.98, 0.00)

• 04:35 PM ET Jul 23, 2025
  

  Can-Fite BioPharma files for offering of up to ~4.9M ADSs/pre-funded warrants and accompanying common warrants through H.C. Wainwright - F-1 ($1.04, 0.00)

• 02:29 PM ET Apr 14, 2025
  

  Can-Fite announces $3.0M registered direct offering of 2.5M ADSs priced at $1.20/ADS through H.C. Wainwright ($1.60, +0.02)

• 01:42 PM ET Apr 14, 2025
  

  Can-Fite BioPharma ADRs halted; news pending ($1.60, +0.02)

• 08:38 AM ET Apr 14, 2025
  

  Can-Fite anticipates $685M in projected future partnership revenues ($1.57, 0.00)

• 08:06 AM ET Apr 14, 2025
  

  Can-Fite BioPharma reports FY EPS ($0.00) vs year-ago ($0.01) ($1.57, 0.00)